Breaking News, Promotions & Moves

WuXi AppTec Appoints Advanced Therapies CEO

Dr. Chang will provide strategic, scientific and operational leadership to the company's global cell and gene therapy R&D and manufacturing services.

By: Contract Pharma

Contract Pharma Staff

WuXi AppTec has appointed Dr. David Chang as Chief Executive Officer of WuXi Advanced Therapies business unit (WuXi ATU), WuXi AppTec’s cell and gene therapy CDMO. In this new executive role, Dr. Chang will provide strategic, scientific and operational leadership to the company’s global cell and gene therapy R&D and manufacturing services. Dr. Chang brings strong leadership and experience in cell and gene therapy and biopharmaceutical technical development, manufacturing opera...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters